Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2013-06-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-013-2219-5PMID 23811982PMCID PMC4653739
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers

  2013cited by this paper
• International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.

  2012cited by this paper
• Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.

  2012cited by this paper
• ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma.

  2012cited by this paper
• Targeting vascular endothelial growth factor in patients with squamous cell lung cancer.

  2012cited by this paper
• Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).

  2012cited by this paper
• Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung.

  2012cited by this paper
• Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

  2011cited by this paper
• Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.

  2011cited by this paper
• BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer

  2011cited by this paper
• Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

  2010cited by this paper
• Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.

  2010cited by this paper
• Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.

  2010cited by this paper
• Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

  2010cited by this paper
• Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.

  2009cited by this paper
• Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

  2009cited by this paper
• Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis

  2009cited by this paper
• Tumor angiogenesis.

  2008cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• VEGF receptor signalling ? in control of vascular function

  2006cited by this paper
• Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

  2004influential reference
• Angiogenesis: Tumorigenesis and the angiogenic switch

  2003cited by this paper
• The biology of VEGF and its receptors

  2003cited by this paper
• Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

  2001cited by this paper
• Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma.

  1998cited by this paper
• Prognostic value of vascular endothelial growth factor and its receptor Flt‐1 in squamous cell lung cancer

  1997cited by this paper
• Hemorrhage from carcinoma of the lung

  1980cited by this paper
• Tumor angiogenesis: therapeutic implications.

  1971cited by this paper
• Transplacental carcinogenesis by stilbestrol.

  1971cited by this paper

• V6 vein-preserving superior segmentectomy: A potentially preferable option

  2024cites this paper
• Volatile organic compounds in exhaled breath: a promising approach for accurate differentiation of lung adenocarcinoma and squamous cell carcinoma

  2024cites this paper
• IRF7 and IFIT2 in mediating different hemorrhage outcomes for non-small cell lung cancer after bevacizumab treatment

  2023cites this paper
• Angiogenesis as a hallmark of solid tumors - clinical perspectives

  2021cites this paper
• Diagnosis of Lung Carcinoma on Small Biopsy.

  2020cites this paper
• Distinct Patterns of mRNA and lncRNA Expression Differences Between Lung Squamous Cell Carcinoma and Adenocarcinoma

  2019cites this paper
• Subtyping Lung Cancer Using DNA Methylation in Liquid Biopsies

  2019cites this paper
• Bevacizumab for non‐small‐cell lung cancer: A nested case control study of risk factors for hemoptysis

  2016cites this paper
• New Discoveries for the Treatment of Lung Cancer and the Role of Small Biopsy Material

  2015cites this paper
• Beyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologies.

  2015cites this paper
• Molecular diagnosis in lung diseases.

  2015cites this paper
• Advances in molecular and immunologic targeted therapies for squamous cell carcinoma of the lung

  2015cites this paper
• Bevacizumab: A Review of Its Use in Advanced Cancer

  2014cites this paper
• Multi-Targeted Antiangiogenic Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer: Meta-Analyses of 20 Randomized Controlled Trials and Subgroup Analyses

  2014cites this paper
• Molecular testing in lung cancer in the era of precision medicine.

  2014cites this paper